Relentlessly fighting a smarter war against GI cancer by partnering with patients based on their unique needs, the Ruesch Center is committed to providing you with the highest standard of care and individualized cures.
At the 2nd Annual Luminary Awards, hosted by OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers, several individuals in the cancer care community were honored for their efforts in improving the lives of patients with gastrointestinal cancers.
ASCO’s chief medical officer Richard L. Schilsky, MD, FACP, FASCO, is among the five gastrointestinal (GI) oncology professionals honored with OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers’ 2018 Luminary Awards in GI Cancers.
Dr. Daniel D. Von Hoff, Distinguished Professor and Physician-In-Chief of the Translational Genomics Research Institute (TGen), an affiliate of the City of Hope, is one of five leading researchers who will receive a Luminary Award in GI Cancers from OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers.
The combination of the PD-L1 inhibitor atezolizumab (Tecentriq) and the VEGF inhibitor bevacizumab (Avastin) showed promising and durable antitumor activity in a phase Ib study of patients with advanced hepatocellular carcinoma (HCC).
Honorees are recognized for their tremendous devotion and leadership in research, clinical care and advocacy in GI cancer.
Sign Up to receive all Ruesch updates directly in your Inbox
We will deliver our quarterly newsletter, monthly updates and other announcements to your Inbox with information on upcoming special events, current clinical trials and cutting edge research and trends in the GI cancer field.